Bioequivalence Study of Trandolapril 4 mg Tablets of Dr. Reddy's Under Fed Conditions

NCT01164800 | Completed Phase 1 DMC

• 1 other identifier: CL-029-TRAN-2006
• Study Type: interventional
• Target: 52
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is

• To compare the single oral dose bioavailability of test product, Trandolapril 4 mg Tablets of Dr. Reddy's and Mavik® 4 mg Tablet of Abbott Laboratories, in healthy, adult, human subjects, under fed conditions to assess bioequivalence.
• To monitor adverse events and ensure safety of subjects.

Conditions

Healthy

Keywords

Bioequivalence; Crossover; Trandolapril

Outcome Measures

Primary Outcomes (1)

• Bioequivalence is based on Cmax and AUC parameters.

  3 months

Study Arms (2)

Trandolapril

EXPERIMENTAL

Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited

Drug: Trandolapril

Mavik®

ACTIVE COMPARATOR

Mavik® 4 mg Tablets of Abbott Laboratories, USA.

Drug: Mavik

Interventions

Trandolapril DRUG

Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited

Also known as: Mavik® 4 mg Tablets

Trandolapril

Mavik DRUG

Mavik® 4 mg Tablets of Abbott Laboratories, USA.

Mavik®

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy human subjects within the age range of 18 to 45 years
• Non-smokers since at least six months
• Willingness to provide written informed consent to participate in the study
• Body-mass index of ≥ 18.5 kg/m2 and ≤24.9 kg/m2, with body weight not less than 50 kg
• Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening Normal 12-lead ECG or one with abnormality considered to be clinically insignificant Normal chest X-ray PA view Comprehension of the nature and purpose of the study and compliance with the requirement of the Protocol
• Female Subjects
• of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm,intrauterine device (IUD), or abstinence, or
• postmenopausal for at least 1 year, or
• surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject

You may not qualify if:

• Personal/family history of allergy or hypersensitivity to Trandolapril or allied drugs
• Past history of anaphylaxis or angioedema
• Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
• Presence of any clinically significCint abnormal values during screening e.g. significant abnormality of Liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
• Any cardiac, renal or liver impairment, any other organ or system impairment
• History of seizure or psychiatric disorders
• Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus
• Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study \[one drink is equal to one unit of alcohol \[one glass wine, half pint beer, and one measure (one ounce) of spirit).
• Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate) within 48 hours before check-in of each period
• Use of any recreational drug or a history of drug addiction
• Participation in any clinical trial within the past 3 months
• Inaccessibility of veins in left and right arm
• Donation of blood (one unit or 350 mL) within 3 months prior to receiVing the first dose of study medication
• Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and until the completion of the study.
• Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs within the last four weeks

Sponsors & Collaborators

• Dr. Reddy's Laboratories Limited: lead

Study Sites (1)

Wellquest Clinical Research

Mumbai, Maharashtra, 400013, India

Location

MeSH Terms

Interventions

trandolapril

Study Officials

• Dr. Umesh Dhakate, M.B.B.S

  Wellquest Clinical Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: July 16, 2010
• First Posted: July 19, 2010
• Study Start: March 1, 2006
• Primary Completion: April 1, 2006
• Study Completion: May 1, 2006
• Last Updated: July 19, 2010

Record last verified: 2010-07

Locations

IN (1)